Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial

MT Newswires Live06-03 03:09

Celcuity (CELC) said Tuesday that detailed results from the Phase 3 Viktoria-1 trial showed its investigational breast cancer treatment gedatolisib outperformed Novartis' (NVS) alpelisib plus fulvestrant in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer.

Celcuity said the gedatolisib plus fulvestrant and palbociclib, or gedatolisib-triplet reduced the risk of disease progression or death by 50% compared with alpelisib plus fulvestrant, and nearly doubled median progression-free survival to 11.1 months from 5.6 months, while gedatolisib plus fulvestrant, or gedatolisib-doublet extended progression-free survival to 11.3 months, with objective response rates of 48.9% and 35.7%, respectively.

The gedatolisib triplet and doublet regimens were generally well tolerated, with mostly low-grade treatment-related adverse events, while overall survival data, a key secondary endpoint, showed promising trends but remain immature. Celcuity plans to submit the data to the US Food and Drug Administration as a supplemental new drug application.

Shares of Celcuity were down more than 25% in Tuesday trading.

Price: 91.65, Change: -31.31, Percent Change: -25.46

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment